AU2016253126B2 - Kappa myeloma antigen chimeric antigen receptors and uses thereof - Google Patents

Kappa myeloma antigen chimeric antigen receptors and uses thereof Download PDF

Info

Publication number
AU2016253126B2
AU2016253126B2 AU2016253126A AU2016253126A AU2016253126B2 AU 2016253126 B2 AU2016253126 B2 AU 2016253126B2 AU 2016253126 A AU2016253126 A AU 2016253126A AU 2016253126 A AU2016253126 A AU 2016253126A AU 2016253126 B2 AU2016253126 B2 AU 2016253126B2
Authority
AU
Australia
Prior art keywords
antigen
receptors
kappa myeloma
chimeric antigen
kappa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016253126A
Other languages
English (en)
Other versions
AU2016253126A1 (en
Inventor
Rosanne Dunn
David Gottlieb
Grant Logan
Kenneth MICKLETHWAITE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemalogix Pty Ltd
Original Assignee
Haemalogix Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemalogix Pty Ltd filed Critical Haemalogix Pty Ltd
Publication of AU2016253126A1 publication Critical patent/AU2016253126A1/en
Application granted granted Critical
Publication of AU2016253126B2 publication Critical patent/AU2016253126B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016253126A 2015-04-23 2016-04-25 Kappa myeloma antigen chimeric antigen receptors and uses thereof Active AU2016253126B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562151968P 2015-04-23 2015-04-23
US62/151,968 2015-04-23
US201562158407P 2015-05-07 2015-05-07
US62/158,407 2015-05-07
PCT/US2016/029203 WO2016172703A2 (en) 2015-04-23 2016-04-25 Kappa myeloma antigen chimeric antigen receptors and uses thereof

Publications (2)

Publication Number Publication Date
AU2016253126A1 AU2016253126A1 (en) 2017-10-12
AU2016253126B2 true AU2016253126B2 (en) 2020-01-30

Family

ID=57143653

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016253126A Active AU2016253126B2 (en) 2015-04-23 2016-04-25 Kappa myeloma antigen chimeric antigen receptors and uses thereof

Country Status (18)

Country Link
US (2) US11305011B2 (OSRAM)
EP (2) EP4368641A3 (OSRAM)
JP (3) JP7229768B2 (OSRAM)
KR (1) KR102623427B1 (OSRAM)
CN (1) CN107922489B (OSRAM)
AU (1) AU2016253126B2 (OSRAM)
BR (1) BR112017022838A2 (OSRAM)
CA (1) CA2978964A1 (OSRAM)
DK (1) DK3286223T5 (OSRAM)
ES (1) ES2976236T3 (OSRAM)
FI (1) FI3286223T3 (OSRAM)
HK (1) HK1252854A1 (OSRAM)
HR (1) HRP20240415T1 (OSRAM)
HU (1) HUE065799T2 (OSRAM)
IL (1) IL255207B2 (OSRAM)
PT (1) PT3286223T (OSRAM)
RU (1) RU2743188C2 (OSRAM)
WO (1) WO2016172703A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3286223T (pt) 2015-04-23 2024-03-22 HaemaLogiX Ltd Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
CN107529550A (zh) * 2017-08-28 2018-01-02 马晓冬 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法
US20200261502A1 (en) * 2017-09-08 2020-08-20 Carsgen Therapeutics Co., Ltd. Genetically engineered t cell and application thereof
WO2019108932A1 (en) * 2017-11-30 2019-06-06 Haemalogix Pty. Ltd. Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells
CN112189018A (zh) * 2018-04-20 2021-01-05 汉诺威医学院 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
WO2020011706A1 (en) 2018-07-09 2020-01-16 Oslo Universitetssykehus Hf Two chimeric antigen receptors specifically binding cd19 and igkappa
CN110832071A (zh) * 2018-09-14 2020-02-21 上海原能细胞医学技术有限公司 表面包含免疫调节剂的细胞及其用途
US20220031840A1 (en) * 2018-12-03 2022-02-03 Haemalogix Pty Ltd Method of Treatment
US20220175833A1 (en) * 2019-03-07 2022-06-09 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
AU2020283811A1 (en) * 2019-05-24 2021-12-16 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and CD47
CN110305906B (zh) * 2019-07-18 2021-11-12 山东大学第二医院 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞
WO2021113853A1 (en) * 2019-12-05 2021-06-10 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
CA3176109A1 (en) * 2020-03-27 2021-09-30 Haemalogix Pty Ltd Composition and method
JP2023525007A (ja) 2020-05-04 2023-06-14 サリオジェン セラピューティクス インコーポレイテッド 転位に基づく療法
WO2021232200A1 (en) * 2020-05-18 2021-11-25 Guangdong Tcrcure Biopharma Technology Co., Ltd. Il-12 armored immune cell therapy and uses thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
US20240352481A1 (en) * 2021-07-29 2024-10-24 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
KR102789265B1 (ko) * 2022-04-14 2025-04-02 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
WO2024196796A1 (en) * 2023-03-17 2024-09-26 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115238A1 (en) * 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US7888479B2 (en) 2002-11-27 2011-02-15 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactric proteins
EP1909836A4 (en) * 2005-08-04 2009-10-14 Univ California METHODS OF TREATING AND DETECTING BETA CELL ASSOCIATED DISEASE
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN105073133B (zh) * 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
PT3286223T (pt) 2015-04-23 2024-03-22 HaemaLogiX Ltd Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115238A1 (en) * 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARFALL., "Immunotherapy with chimeric antigen receptors for multiple myeloma.", Discov Med., (2014), vol. 17, no. 91, pages 37 - 46 *
J. VERA ET AL, "T lymphocytes redirected against the ? light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells", BLOOD, US, (2006-12-01), vol. 108, no. 12, pages 3890 - 3897 *

Also Published As

Publication number Publication date
WO2016172703A2 (en) 2016-10-27
DK3286223T5 (da) 2024-10-07
RU2743188C2 (ru) 2021-02-16
EP3286223B8 (en) 2024-04-03
KR20170139044A (ko) 2017-12-18
HRP20240415T1 (hr) 2025-05-23
KR102623427B1 (ko) 2024-01-12
HK1251586A1 (en) 2019-02-01
RU2017138528A3 (OSRAM) 2019-09-03
HK1252854A1 (zh) 2019-06-06
IL255207B2 (en) 2023-09-01
RU2017138528A (ru) 2019-05-07
CN107922489B (zh) 2022-02-25
AU2016253126A1 (en) 2017-10-12
CN107922489A (zh) 2018-04-17
EP3286223B1 (en) 2024-02-28
ES2976236T3 (es) 2024-07-29
BR112017022838A2 (pt) 2018-07-17
EP4368641A3 (en) 2024-08-14
EP3286223A4 (en) 2018-12-05
EP4368641A2 (en) 2024-05-15
PT3286223T (pt) 2024-03-22
HUE065799T2 (hu) 2024-06-28
US20180228892A1 (en) 2018-08-16
US11305011B2 (en) 2022-04-19
US20220193232A1 (en) 2022-06-23
CA2978964A1 (en) 2016-10-27
JP7229768B2 (ja) 2023-02-28
IL255207A0 (en) 2017-12-31
FI3286223T3 (fi) 2024-03-25
IL255207B1 (en) 2023-05-01
JP2018519356A (ja) 2018-07-19
JP2021073312A (ja) 2021-05-13
JP2023024793A (ja) 2023-02-16
EP3286223A2 (en) 2018-02-28
NZ735778A (en) 2024-03-22
WO2016172703A3 (en) 2016-11-24
DK3286223T3 (da) 2024-04-02

Similar Documents

Publication Publication Date Title
EP3286223B8 (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
ZA201803874B (en) Humanized anti-cd73 antibodies
EP3256496A4 (en) Chimeric antigen receptors
IL258527A (en) Chimeric Antigen Receptors Against Sorting Group 30
EP3134434A4 (en) Kappa/lambda chimeric antigen receptors
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
EP3274366B8 (en) Chimeric antigen receptor
EP3256492A4 (en) Bi-specific chimeric antigen receptor and uses thereof
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
HUE056769T2 (hu) Humanizált anti-CD40 antitestek és felhasználásuk
IL259492B (en) Humanized antibodies against cll–1
GB201617290D0 (en) Novel chimeric antigen receptors
PT3674315T (pt) Recetores de antigénios quiméricos, composições e métodos
EP3204422A4 (en) Humanized anti-ox40 antibodies and uses thereof
ZA201807167B (en) Humanized anti-il-1r3 antibodies
IL254514B (en) Anti-human notch4 antibody
IL256579A (en) Human antibodies
EP3103811A4 (en) Anti-tissue factor monoclonal antibody
EP3137502A4 (en) Humanized antibodies against ceacam1
EP3131581A4 (en) Humanized anti-tf-antigen antibodies
EP3187583A4 (en) Monoclonal antibody against kir2ds1
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
HK40094580A (zh) 人源化抗il-1r3抗体
HK40111469A (zh) 人源化或嵌合cd3抗体
GB201511196D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)